Since introducing our first Factor VIII (FVIII) concentrate, we have dedicated ourselves to advancing the safety and efficacy of the factor VIII treatment we manufacture for patients with haemophilia A. We also strive to provide the bleeding disorders community with the tools, associated support programmes, and resources that can facilitate an improvement in the quality of life for those patients.

Chugai Pharma

Chugai Pharma UK Ltd is a research-based pharmaceutical company, part of the Roche group. Our mission is to provide innovative medical products and services, for the benefit of the UK medical community and the patients in its care. Chugai is a Japanese global company, with a rich history and strong position in a number of therapeutic areas including: oncology, haematology and rheumatology, and a growing research pipeline including novel targeted therapies and supportive care agents. Chugai is committed to the highest ethical and moral standards in order to fulfil its corporate social responsibility to society.

CSL Behring

CSL Behring is a global leader in the plasma protein biotherapeutics industry. We research, develop, manufacture and market biotherapies, which are used to treat serious and rare conditions. At CSL Behring, we are passionate about improving the quality of life of people with rare diseases, including primary immune deficiencies, haemophilia and von Willebrand disease. our therapies also help prevent blood-related diseases in newborns. Through our continued focus on innovation, we are leaders in developing new and enhanced plasma-derived and recombinant biotherapies, with a 100-year heritage of quality and safety.


Founded in 1940, Grifols is a global healthcare company whose mission is to improve the health and well-being of people around the world. This is achieved by producing life-saving protein therapies for patients and by providing hospitals, pharmacies and healthcare professionals with the tools they need to deliver expert medical care.
Grifols has a long tradition in supporting and encouraging clinical research. We are therefore proud to support The Journal of Haemophilia Practice. The Journal provides a platform for healthcare professionals to contribute knowledge and expertise in order to continue developing our understanding of inherited bleeding disorders. We welcome the opportunity to provide support in this key area.


We are pleased to announce the establishment of LFB Biopharmaceuticals in the UK. Founded in France 20 years ago with the aim of developing increasing safety for plasma-derived pharmaceuticals, today the LFB Group includes companies with expertise in plasma fractionation, cell culture and recombinant technologies. We develop, manufacture and market medicinal products for the treatment of serious, and often rare, diseases in several major therapeutic fields, including Haemostasis, Immunology and Intensive Care.

Novo Nordisk

Headquartered in Denmark, Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Novo Nordisk employs approximately 41,000 employees in 75 countries, and markets its products in more than 180 countries.


Octapharma Ltd, based in Manchester in the UK and with global headquarters in Switzerland, has a clear and consistent mission, “for the safe and optimal use of human proteins”. Octapharma has implemented a strategy of continuous investment in existing products and innovative projects, to develop a world-class portfolio of human proteins from human plasma and human cell-lines. Patients in more than 100 countries are treated with products in the following therapeutic areas: haematology (coagulation disorders), immunotherapy (immune disorders) and critical care.


At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world’s best-known consumer products. Every day, Pfizer colleagues work to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world’s leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. In the UK, Pfizer has its business headquarters in Surrey and is a major supplier of medicines to the NHS.


Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. It is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. For more than 20 years, Roche has been developing medicines that redefine treatment in haematology. Today, we are investing more than ever in our effort to bring innovative treatment options to people with diseases of the blood. Roche’s dedication to developing novel molecules in haematology expands beyond malignancy, with the development of Hemlibra (emicizumab), a bispecific monoclonal antibody for the treatment of haemophilia A.


Sobi is a Swedish specialty pharmaceutical company with focus on providing and developing specialist pharmaceuticals for rare disease patients with high unmet medical needs. Our portfolio consists of 60 marketed products, and we have an emerging late stage clinical development pipe-line focused on rare diseases. Currently we are researching new treatments for patients with haemophilia, using forward thinking to apply established technology to advance haemophilia research.


Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Neuroscience and Rare Diseases. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. Our experience as leaders in haematology means we are well prepared to meet today’s needs as we pursue future developments in the care of bleeding disorders. Together with the haematology community, we are raising expectations for the future, including earlier diagnosis, earlier and full protection against bleeds, and more personalised patient care.  Shire is now part of Takeda.  For more information, please visit our website.